Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been reapproved for heart failure (HF) therapy in patients with and without diabetes. However, the initial glucose-lowering indication of SGLT2i has impeded their uses in cardiovascular clinical practice. A challenge of SGLT2i then becomes how t...

Full description

Bibliographic Details
Main Authors: Yixiang Xu, Chao Zhang, Kai Jiang, Xinchun Yang, Feng Chen, Zhiyang Cheng, Jinlong Zhao, Jiaxing Cheng, Xiaokang Li, Xin Chen, Luoyifan Zhou, Hao Duan, Yunyuan Huang, Yaozu Xiang, Jian Li
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Heart failure
SGLT2 inhibitor
Empagliflozin
Structural repurposing
NHE1 (sodium-hydrogen exchanger 1)
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383522003860

Internet

http://www.sciencedirect.com/science/article/pii/S2211383522003860

Similar Items